News

Press Releases

Found 32 Results

December 6, 2025

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

MAINZ, Germany, and ROCKVILLE, USA, December 6, 2025 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”) today presented data […]

October 27, 2025

China’s NMPA Grants Breakthrough Therapy Designation for Anti-CTLA-4 Antibody Candidate Gotistobart (BNT316/ONC-392)

Designation granted for gotistobart (BNT316/ONC392) for the treatment of patients with squamous non-small cell lung cancer (sqNSCLC), an aggressive subtype […]

October 2, 2025

OncoC4 Closes Nearly $50 Million in Series B Financing to Advance Multiple Pipeline Candidates

ROCKVILLE, Md., Oct. 02, 2025 — OncoC4, Inc. a clinical-stage biotechnology company, today announced the recent closing of a Series […]

September 8, 2025

OncoC4 to Present Global Pivotal Phase 3 Trial Design for Next-Generation CTLA-4 Antibody Gotistobart Monotherapy Being Co-Developed with BioNTech in NSCLC at the IASLC 2025 World Conference on Lung Cancer

PRESERVE-003 is evaluating gotistobart vs. docetaxel in patients with squamous non-small cell lung cancer (sqNSCLC) who have progressed on chemotherapy […]

August 18, 2025

OncoC4 Strengthens Leadership Team with Appointment of Shiniu Wei as Chief Financial Officer

ROCKVILLE, Maryland, August 18, 2025 (GLOBE NEWSWIRE) –– OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer today […]